PUBLICATION,RELATION,AIDA-SENTENCE
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The cholinesterase inhibitor donepezil is efficacious for treating mild to moderate Alzheimer's disease."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The cholinesterase inhibitor galantamine is efficacious for treating mild to moderate Alzheimer's disease."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The cholinesterase inhibitor rivastigmine is efficacious for treating mild to moderate Alzheimer's disease."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The three cholinesterase inhibitors donepezil, galantamine, and rivastigmine have about the same efficacy for treating mild to moderate Alzheimer's disease."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"Out of the two cholinesterase inhibitors donepezil and rivastigmine, donepezil leads to fewer adverse events when used for treating mild to moderate Alzheimer's disease."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' cognitive function."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' abilities to carry out activities of daily living."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine reduces the patients' behavioral disturbance from the disease."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the global assessment of the patients' conditions."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine leads to an increased probability of many types of adverse events."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score on the Alzheimer's Disease Assessment Scale (ADAS-Cog)."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Mini Mental State Examination (MMSE)."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Disability Assessment for Dementia (DAD)."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Progressive Deterioration Scale (PDS)."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score obtained by the Neuropsychiatric Instrument (NPI)."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Clinician's Interview-Based Impression of Change scale (CIBIC-Plus)."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of the patient's withdrawal before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of the patient's withdrawal due to an adverse event before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of adverse events before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of abdominal pain before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of abnormal gait before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of abnormal dreams before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of accidental injury before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of agitation before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of anorexia before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of anxiety before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of arthralgia before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of asthenia before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of back pain before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of confusion before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of conjunctivitis before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of constipation before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of depression before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of diarrhoea before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of dizziness before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of ecchymosis before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of fatigue before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of fever before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of fracture before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of haemorrhage before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of headache before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of hostility before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of increased cough before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of infection before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of insomnia before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of muscle cramp before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of myasthenia before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of nausea before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of pain before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of peripheral oedema before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of rash before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of respiratory tract infection before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of rhinitis before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of skin ulcer before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of syncope before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of tremor before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of urinary tract infection before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of vertigo before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of vomiting before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,claims,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of weight loss before the end of the treatment as compared to a placebo treatment."
http://dx.doi.org/10.1002/14651858.CD005593,reviews,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Gottfries, Brane, and Steen scale (GBS)."
http://dx.doi.org/10.1002/14651858.CD005593,reviews,"The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine reduces the time needed by carers to assist in instrumental activities of daily living and physical self-maintenance."
